Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ass. Prof. Jan Nyman
This is an open label, multicentre phase II trial of individually escalated radiotherapy up to 84 Gy due to normal tissue dose constraints combined with standard concurrent chemotherapy (cisplatin-vinorelbine) compared to standard dose radiotherapy (68 Gy) combined with the same chemotherapy. There are restrictions due to lung function, performance status and pre-treatment weight loss. The main endpoint is progression free survival and additional endpoints are local control, overall survival, toxicity quality of life and relapse pattern.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological diagnosis of NSCLC stage IIIA-B.
Nonresectable or medically inoperable patients.
No prior chemo- or radiotherapy for NSCLC.
PS 0-1.
FEV1 \> 1 l or \> 40% and CO diffusion capacity \> 40%.
Patient compliance and geographic proximity that allow adequate follow-up.